Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 872

1.

Low-density lipoprotein cholesterol: Lower is Better.

Cannon CP.

J Am Coll Cardiol. 2020 Mar 21. pii: S0735-1097(20)34639-8. doi: 10.1016/j.jacc.2020.03.033. [Epub ahead of print] No abstract available.

PMID:
32209335
2.

Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Baccara-Dinet MT, Zhao J, Donahue S, Ali S, Manvelian G, Pordy R.

J Clin Lipidol. 2020 Jan - Feb;14(1):88-97.e2. doi: 10.1016/j.jacl.2020.01.001. Epub 2020 Jan 13.

3.

Reply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes.

Maeng M, Bhatt DL, Nordaby M, Miede C, Cannon CP; RE-DUAL PCI Investigators.

JACC Cardiovasc Interv. 2020 Mar 9;13(5):658-659. doi: 10.1016/j.jcin.2020.01.207. No abstract available.

PMID:
32139229
4.

Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial.

Fanaroff AC, Peterson ED, Kaltenbach LA, Cannon CP, Choudhry NK, Henry TD, Anstrom KJ, Cohen DJ, Fonseca E, Khan ND, Fonarow GC, Wang TY.

JAMA Cardiol. 2020 Mar 4. doi: 10.1001/jamacardio.2020.0125. [Epub ahead of print]

PMID:
32129795
5.

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.

Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Vranckx P, Goette A, Gibson CM, Alexander JH.

JAMA Cardiol. 2020 Feb 26. doi: 10.1001/jamacardio.2019.6175. [Epub ahead of print]

PMID:
32101251
6.

Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin.

Nanna MG, Navar AM, Giugliano RP, White JA, Lokhnygina Y, Mitchel YB, Musliner TA, Cannon CP, Blazing MA.

J Am Coll Cardiol. 2020 Feb 25;75(7):835-837. doi: 10.1016/j.jacc.2019.12.022. No abstract available.

PMID:
32081289
7.

Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B.

J Am Heart Assoc. 2020 Feb 4;9(3):e014908. doi: 10.1161/JAHA.119.014908. Epub 2020 Jan 29.

8.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation.

Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP.

J Am Coll Cardiol. 2020 Jan 21;75(2):238-240. doi: 10.1016/j.jacc.2019.11.012. No abstract available.

PMID:
31948654
9.

Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).

Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

Am J Cardiol. 2020 Mar 1;125(5):735-743. doi: 10.1016/j.amjcard.2019.11.029. Epub 2019 Dec 9.

10.

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.

Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F.

J Am Heart Assoc. 2020 Jan 7;9(1):e012797. doi: 10.1161/JAHA.119.012797. Epub 2020 Jan 4.

11.

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.

Bach RG, Cannon CP, Blazing MA.

JAMA Cardiol. 2020 Jan 2. doi: 10.1001/jamacardio.2019.5241. [Epub ahead of print] No abstract available.

PMID:
31895449
12.

Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.

Thomas MR, James SK, Becker RC, Himmelmann A, Katus HA, Cannon CP, Steg PG, Siegbahn A, Lakic T, Storey RF, Wallentin L.

Eur Heart J Acute Cardiovasc Care. 2019 Dec 23:2048872619878075. doi: 10.1177/2048872619878075. [Epub ahead of print]

PMID:
31868508
13.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.

Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue ML.

J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022. doi: 10.1016/j.jacc.2019.09.065. Epub 2019 Dec 9.

PMID:
31865968
14.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.

Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Dec 9;12(23):2346-2355. doi: 10.1016/j.jcin.2019.07.059.

15.

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.

Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Dec 9;12(23):2331-2341. doi: 10.1016/j.jcin.2019.08.039.

PMID:
31806214
16.

Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.

Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Yazdi D, Elliott-Davey M, Mues KE, Bhatt DL, Kosiborod MN; GOULD Investigators.

Am Heart J. 2020 Jan;219:70-77. doi: 10.1016/j.ahj.2019.10.014. Epub 2019 Oct 31.

17.

Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.

Fanaroff AC, Peterson ED, Kaltenbach LA, Cannon CP, Choudhry NK, Henry TD, Anstrom KJ, Cohen DJ, Fonseca E, Khan ND, Fonarow GC, Wang TY.

JAMA Cardiol. 2019 Nov 13. doi: 10.1001/jamacardio.2019.4408. [Epub ahead of print]

PMID:
31721978
18.

Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.

Robinson JG, Farnier M, Kastelein JJP, Roth EM, Taskinen MR, Colhoun HM, Brunet A, DiCioccio AT, Lecorps G, Pordy R, Baccara-Dinet MT, Cannon CP.

J Clin Lipidol. 2019 Nov - Dec;13(6):979-988.e10. doi: 10.1016/j.jacl.2019.10.004. Epub 2019 Oct 14.

19.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.

Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW.

Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11. No abstract available.

PMID:
31707795
20.

Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI: Time in Therapeutic Range.

Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CP.

J Am Coll Cardiol. 2019 Nov 12;74(19):2431-2433. doi: 10.1016/j.jacc.2019.09.009. No abstract available.

PMID:
31699285
21.

Interleukin-18 in patients with acute coronary syndromes.

Åkerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, Himmelmann A, Katus HA, Storey RF, Wallentin L, Weaver WD, Siegbahn A; PLATO Investigators.

Clin Cardiol. 2019 Dec;42(12):1202-1209. doi: 10.1002/clc.23274. Epub 2019 Oct 9.

22.

Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry.

Divakaran S, Singh A, Biery D, Yang J, DeFilippis EM, Collins BL, Ramsis M, Qamar A, Hainer J, Klein J, Cannon CP, Polk DM, Plutzky J, Nasir K, Januzzi JL, Di Carli MF, Bhatt DL, Blankstein R.

Diabetes Care. 2019 Sep 23. pii: dc190998. doi: 10.2337/dc19-0998. [Epub ahead of print]

PMID:
31548242
23.

Don't stop the statin!

Cannon CP.

Eur Heart J. 2019 Nov 14;40(43):3526-3528. doi: 10.1093/eurheartj/ehz629. No abstract available.

PMID:
31495878
24.

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.

Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.

JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050.

PMID:
31439336
25.

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.

Qamar A, Giugliano RP, Bohula EA, Park JG, Jarolim P, Murphy SA, Blazing MA, Califf RM, Cannon CP, Braunwald E, Morrow DA.

J Am Coll Cardiol. 2019 Aug 27;74(8):1057-1068. doi: 10.1016/j.jacc.2019.06.038.

PMID:
31439215
26.

Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.

Cannon CP, Khan I, Klimchak AC, Sanchez RJ, Sasiela WJ, Massaro JM, D'Agostino RB, Reynolds MR.

Am Heart J. 2019 Oct;216:30-41. doi: 10.1016/j.ahj.2019.06.005. Epub 2019 Jun 12.

27.

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.

Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.

Atherosclerosis. 2019 Sep;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. Epub 2019 Jul 12.

28.

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.

Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA.

JAMA Cardiol. 2019 Jul 17. doi: 10.1001/jamacardio.2019.2306. [Epub ahead of print]

PMID:
31314050
29.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

30.

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.

Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ.

J Am Coll Cardiol. 2019 Jul 9;74(1):83-99. doi: 10.1016/j.jacc.2019.05.016. Review.

PMID:
31272556
31.

Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®.

Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, Januzzi JL Jr.

ESC Heart Fail. 2019 Aug;6(4):784-792. doi: 10.1002/ehf2.12455. Epub 2019 Jul 3.

32.

Alteration of medical therapy in patients with heart failure relative to change in symptom severity.

Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, Alexanian C, Januzzi JL Jr.

ESC Heart Fail. 2019 Oct;6(5):1085-1087. doi: 10.1002/ehf2.12480. Epub 2019 Jul 3.

33.

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.

Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.

Atherosclerosis. 2019 Sep;288:194-202. doi: 10.1016/j.atherosclerosis.2019.06.896. Epub 2019 Jun 8.

34.

Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.

Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, Granger CB, Verheugt FWA, Li J, Ten Berg JM, Sarafoff N, Gibson CM, Alexander JH.

JAMA Cardiol. 2019 Jun 19. doi: 10.1001/jamacardio.2019.1880. [Epub ahead of print]

PMID:
31215979
35.

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.

Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M; GOULD Investigators.

Circulation. 2019 Aug 13;140(7):618-620. doi: 10.1161/CIRCULATIONAHA.119.041730. Epub 2019 Jun 7. No abstract available.

PMID:
31174429
36.

Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, Cannon CP, Katus HA, Himmelmann A, Storey RF, Becker RC, Lopes RD; PLATO Investigators.

Am Heart J. 2019 Jul;213:57-65. doi: 10.1016/j.ahj.2019.04.006. Epub 2019 Apr 18.

PMID:
31108273
37.

Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction.

Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, Lopez JAG, de Ferranti SD, Plutzky J, Cannon CP, Januzzi JL Jr, Di Carli MF, Nasir K, Bhatt DL, Blankstein R.

J Am Coll Cardiol. 2019 May 21;73(19):2439-2450. doi: 10.1016/j.jacc.2019.02.059.

PMID:
31097165
38.

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.

Bruckert E, Kereiakes DJ, Koren MJ, Louie MJ, Letierce A, Miller K, Cannon CP.

J Clin Lipidol. 2019 May - Jun;13(3):443-454. doi: 10.1016/j.jacl.2019.04.005. Epub 2019 Apr 10.

39.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

40.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1.

PMID:
30928824
41.

Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.

Vaduganathan M, Patel RB, Singh A, McCarthy CP, Qamar A, Januzzi JL Jr, Scirica BM, Butler J, Cannon CP, Bhatt DL.

J Am Coll Cardiol. 2019 Apr 2;73(12):1596-1598. doi: 10.1016/j.jacc.2019.01.029. No abstract available.

42.

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.

Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP.

Eur Heart J. 2019 May 14;40(19):1553-1562. doi: 10.1093/eurheartj/ehz059.

43.

Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.

Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS.

Am J Cardiol. 2019 Apr 15;123(8):1202-1207. doi: 10.1016/j.amjcard.2019.01.028. Epub 2019 Jan 25.

44.

Medication Discontinuation in the IMPROVE-IT Trial.

Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. doi: 10.1161/CIRCOUTCOMES.118.005041.

45.

Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.

Wang TY, Kaltenbach LA, Cannon CP, Fonarow GC, Choudhry NK, Henry TD, Cohen DJ, Bhandary D, Khan ND, Anstrom KJ, Peterson ED.

JAMA. 2019 Jan 1;321(1):44-55. doi: 10.1001/jama.2018.19791.

46.

Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry.

Fan W, Song Y, Inzucchi SE, Sperling L, Cannon CP, Arnold SV, Kosiborod M, Wong ND.

Diabetes Obes Metab. 2019 May;21(5):1121-1127. doi: 10.1111/dom.13625. Epub 2019 Feb 14.

PMID:
30609214
47.

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B.

Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.

48.

Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry.

Contreras JP, Hong KN, Castillo J, Marzec LN, Hsu JC, Cannon CP, Yang S, Maddox TM.

Clin Cardiol. 2019 Mar;42(3):339-345. doi: 10.1002/clc.23142. Epub 2019 Jan 30.

49.

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP.

Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722. Review.

PMID:
30571525
50.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800

Supplemental Content

Loading ...
Support Center